Cohort demographics and clinical characteristics of the total group, Rotterdam cohort and LAS cohort
| . | Total cohort (n = 622) . | Rotterdam cohort (n = 194) . | LAS cohort (n = 428) . |
|---|---|---|---|
| Age at diagnosis (years) | 46.0 (36.0–55.0) | 49.0 (39.8–58.0) | 44.0 (34.0–53.0)* |
| Sex (female) | 295 (47.4) | 95 (49.0) | 200 (46.7) |
| Bodyweight (kg) | 82.8 (71.0–96.4) | 90.0 (75.2–100.1) | 80.0 (70.0–95.0)* |
| Height (cm) | 172.0 (166.0–180.0) | 176.0 (168.8–182.3) | 172.0 (165.0–179.3)* |
| Nadir GH at diagnosis (µg/L) | 5.8 (2.4–15.3) | 4.3 (1.9–10.6) | 6.0 (2.5–18.0)* |
| GH at diagnosis (µg/L) | 8.5 (3.9–21.8) | 12.2 (5.9–28.3) | 7.3 (3.6–19.8)* |
| IGF-1 at diagnosis (×ULN) | 2.7 (2.0–3.6) | 2.9 (2.4–4.1) | 2.6 (1.9–3.5)* |
| Tumor size | |||
| Microadenoma | 103 (16.7) | 46 (23.7) | 57 (13.5)* |
| Macroadenoma | 493 (80.2) | 144 (74.2) | 349 (81.5)* |
| Nonvisible adenoma | 19 (3.1) | 4 (2.1) | 15 (3.5) |
| Presence of type 2 DM | 227 (36.5) | 76 (39.2) | 151 (35.3) |
| Oral medication | 196 (31.5) | 66 (34.0) | 130 (30.4) |
| Insulin therapy | 44 (7.1) | 10 (5.2) | 34 (7.9) |
| Previous treatment | |||
| Surgery | 205 (33.0) | 38 (19.6) | 167 (39.0)* |
| Surgical reintervention | 22 (3.5) | 8 (18.6) | 14 (8.4) |
| Medical treatment | 111 (17.8) | 12 (6.2) | 99 (23.1)* |
| Panhypopituitarism | 44 (7.1) | 27 (13.9) | 17 (4.0)* |
| Age at baseline (years) | 47.0 (37.0–56.5) | 50.0 (40.0–59.0) | 46.0 (36.0–55.0)* |
| GH at baseline (µg/L) | 7.6 (3.5–20.1) | 8.1 (3.2–21.8) | 7.3 (3.6–19.9) |
| IGF-1 at baseline (x ULN) | 2.7 (1.9–3.6) | 2.9 (2.2–4.1) | 2.6 (1.9–3.5)* |
| Octreotide LAR | 311 (50) | 123 (63.4) | 188 (43.9)* |
| Treatment response | |||
| Biochemical response | 498 (80.1) | 114 (58.8) | 384 (89.7)* |
| Partial response | 79 (12.7) | 50 (25.8) | 29 (6.8)* |
| Non-response | 45 (7.2) | 30 (15.5) | 15 (3.5)* |
| Duration fg-SRL therapy (months) | 132.4 (36.4–215.3) | 17.7 (8.5–66.7) | 177.2 (116.7–243.3)* |
| . | Total cohort (n = 622) . | Rotterdam cohort (n = 194) . | LAS cohort (n = 428) . |
|---|---|---|---|
| Age at diagnosis (years) | 46.0 (36.0–55.0) | 49.0 (39.8–58.0) | 44.0 (34.0–53.0)* |
| Sex (female) | 295 (47.4) | 95 (49.0) | 200 (46.7) |
| Bodyweight (kg) | 82.8 (71.0–96.4) | 90.0 (75.2–100.1) | 80.0 (70.0–95.0)* |
| Height (cm) | 172.0 (166.0–180.0) | 176.0 (168.8–182.3) | 172.0 (165.0–179.3)* |
| Nadir GH at diagnosis (µg/L) | 5.8 (2.4–15.3) | 4.3 (1.9–10.6) | 6.0 (2.5–18.0)* |
| GH at diagnosis (µg/L) | 8.5 (3.9–21.8) | 12.2 (5.9–28.3) | 7.3 (3.6–19.8)* |
| IGF-1 at diagnosis (×ULN) | 2.7 (2.0–3.6) | 2.9 (2.4–4.1) | 2.6 (1.9–3.5)* |
| Tumor size | |||
| Microadenoma | 103 (16.7) | 46 (23.7) | 57 (13.5)* |
| Macroadenoma | 493 (80.2) | 144 (74.2) | 349 (81.5)* |
| Nonvisible adenoma | 19 (3.1) | 4 (2.1) | 15 (3.5) |
| Presence of type 2 DM | 227 (36.5) | 76 (39.2) | 151 (35.3) |
| Oral medication | 196 (31.5) | 66 (34.0) | 130 (30.4) |
| Insulin therapy | 44 (7.1) | 10 (5.2) | 34 (7.9) |
| Previous treatment | |||
| Surgery | 205 (33.0) | 38 (19.6) | 167 (39.0)* |
| Surgical reintervention | 22 (3.5) | 8 (18.6) | 14 (8.4) |
| Medical treatment | 111 (17.8) | 12 (6.2) | 99 (23.1)* |
| Panhypopituitarism | 44 (7.1) | 27 (13.9) | 17 (4.0)* |
| Age at baseline (years) | 47.0 (37.0–56.5) | 50.0 (40.0–59.0) | 46.0 (36.0–55.0)* |
| GH at baseline (µg/L) | 7.6 (3.5–20.1) | 8.1 (3.2–21.8) | 7.3 (3.6–19.9) |
| IGF-1 at baseline (x ULN) | 2.7 (1.9–3.6) | 2.9 (2.2–4.1) | 2.6 (1.9–3.5)* |
| Octreotide LAR | 311 (50) | 123 (63.4) | 188 (43.9)* |
| Treatment response | |||
| Biochemical response | 498 (80.1) | 114 (58.8) | 384 (89.7)* |
| Partial response | 79 (12.7) | 50 (25.8) | 29 (6.8)* |
| Non-response | 45 (7.2) | 30 (15.5) | 15 (3.5)* |
| Duration fg-SRL therapy (months) | 132.4 (36.4–215.3) | 17.7 (8.5–66.7) | 177.2 (116.7–243.3)* |
Data are mean (SD), median (IQR) or n (%). Asterisk represents P = ≤.05 for the comparisons between Rotterdam and LAS cohort and are derived from the Student’s t test (continuous variables) and Pearson’s chi-square test (categorical variables).
Abbreviations: IGF-1, insulin-like growth factor 1; fg-SRL, first-generation somatostatin receptor ligand; Octreotide LAR, Octreotide long-acting release; ULN, upper limit of normal.
Cohort demographics and clinical characteristics of the total group, Rotterdam cohort and LAS cohort
| . | Total cohort (n = 622) . | Rotterdam cohort (n = 194) . | LAS cohort (n = 428) . |
|---|---|---|---|
| Age at diagnosis (years) | 46.0 (36.0–55.0) | 49.0 (39.8–58.0) | 44.0 (34.0–53.0)* |
| Sex (female) | 295 (47.4) | 95 (49.0) | 200 (46.7) |
| Bodyweight (kg) | 82.8 (71.0–96.4) | 90.0 (75.2–100.1) | 80.0 (70.0–95.0)* |
| Height (cm) | 172.0 (166.0–180.0) | 176.0 (168.8–182.3) | 172.0 (165.0–179.3)* |
| Nadir GH at diagnosis (µg/L) | 5.8 (2.4–15.3) | 4.3 (1.9–10.6) | 6.0 (2.5–18.0)* |
| GH at diagnosis (µg/L) | 8.5 (3.9–21.8) | 12.2 (5.9–28.3) | 7.3 (3.6–19.8)* |
| IGF-1 at diagnosis (×ULN) | 2.7 (2.0–3.6) | 2.9 (2.4–4.1) | 2.6 (1.9–3.5)* |
| Tumor size | |||
| Microadenoma | 103 (16.7) | 46 (23.7) | 57 (13.5)* |
| Macroadenoma | 493 (80.2) | 144 (74.2) | 349 (81.5)* |
| Nonvisible adenoma | 19 (3.1) | 4 (2.1) | 15 (3.5) |
| Presence of type 2 DM | 227 (36.5) | 76 (39.2) | 151 (35.3) |
| Oral medication | 196 (31.5) | 66 (34.0) | 130 (30.4) |
| Insulin therapy | 44 (7.1) | 10 (5.2) | 34 (7.9) |
| Previous treatment | |||
| Surgery | 205 (33.0) | 38 (19.6) | 167 (39.0)* |
| Surgical reintervention | 22 (3.5) | 8 (18.6) | 14 (8.4) |
| Medical treatment | 111 (17.8) | 12 (6.2) | 99 (23.1)* |
| Panhypopituitarism | 44 (7.1) | 27 (13.9) | 17 (4.0)* |
| Age at baseline (years) | 47.0 (37.0–56.5) | 50.0 (40.0–59.0) | 46.0 (36.0–55.0)* |
| GH at baseline (µg/L) | 7.6 (3.5–20.1) | 8.1 (3.2–21.8) | 7.3 (3.6–19.9) |
| IGF-1 at baseline (x ULN) | 2.7 (1.9–3.6) | 2.9 (2.2–4.1) | 2.6 (1.9–3.5)* |
| Octreotide LAR | 311 (50) | 123 (63.4) | 188 (43.9)* |
| Treatment response | |||
| Biochemical response | 498 (80.1) | 114 (58.8) | 384 (89.7)* |
| Partial response | 79 (12.7) | 50 (25.8) | 29 (6.8)* |
| Non-response | 45 (7.2) | 30 (15.5) | 15 (3.5)* |
| Duration fg-SRL therapy (months) | 132.4 (36.4–215.3) | 17.7 (8.5–66.7) | 177.2 (116.7–243.3)* |
| . | Total cohort (n = 622) . | Rotterdam cohort (n = 194) . | LAS cohort (n = 428) . |
|---|---|---|---|
| Age at diagnosis (years) | 46.0 (36.0–55.0) | 49.0 (39.8–58.0) | 44.0 (34.0–53.0)* |
| Sex (female) | 295 (47.4) | 95 (49.0) | 200 (46.7) |
| Bodyweight (kg) | 82.8 (71.0–96.4) | 90.0 (75.2–100.1) | 80.0 (70.0–95.0)* |
| Height (cm) | 172.0 (166.0–180.0) | 176.0 (168.8–182.3) | 172.0 (165.0–179.3)* |
| Nadir GH at diagnosis (µg/L) | 5.8 (2.4–15.3) | 4.3 (1.9–10.6) | 6.0 (2.5–18.0)* |
| GH at diagnosis (µg/L) | 8.5 (3.9–21.8) | 12.2 (5.9–28.3) | 7.3 (3.6–19.8)* |
| IGF-1 at diagnosis (×ULN) | 2.7 (2.0–3.6) | 2.9 (2.4–4.1) | 2.6 (1.9–3.5)* |
| Tumor size | |||
| Microadenoma | 103 (16.7) | 46 (23.7) | 57 (13.5)* |
| Macroadenoma | 493 (80.2) | 144 (74.2) | 349 (81.5)* |
| Nonvisible adenoma | 19 (3.1) | 4 (2.1) | 15 (3.5) |
| Presence of type 2 DM | 227 (36.5) | 76 (39.2) | 151 (35.3) |
| Oral medication | 196 (31.5) | 66 (34.0) | 130 (30.4) |
| Insulin therapy | 44 (7.1) | 10 (5.2) | 34 (7.9) |
| Previous treatment | |||
| Surgery | 205 (33.0) | 38 (19.6) | 167 (39.0)* |
| Surgical reintervention | 22 (3.5) | 8 (18.6) | 14 (8.4) |
| Medical treatment | 111 (17.8) | 12 (6.2) | 99 (23.1)* |
| Panhypopituitarism | 44 (7.1) | 27 (13.9) | 17 (4.0)* |
| Age at baseline (years) | 47.0 (37.0–56.5) | 50.0 (40.0–59.0) | 46.0 (36.0–55.0)* |
| GH at baseline (µg/L) | 7.6 (3.5–20.1) | 8.1 (3.2–21.8) | 7.3 (3.6–19.9) |
| IGF-1 at baseline (x ULN) | 2.7 (1.9–3.6) | 2.9 (2.2–4.1) | 2.6 (1.9–3.5)* |
| Octreotide LAR | 311 (50) | 123 (63.4) | 188 (43.9)* |
| Treatment response | |||
| Biochemical response | 498 (80.1) | 114 (58.8) | 384 (89.7)* |
| Partial response | 79 (12.7) | 50 (25.8) | 29 (6.8)* |
| Non-response | 45 (7.2) | 30 (15.5) | 15 (3.5)* |
| Duration fg-SRL therapy (months) | 132.4 (36.4–215.3) | 17.7 (8.5–66.7) | 177.2 (116.7–243.3)* |
Data are mean (SD), median (IQR) or n (%). Asterisk represents P = ≤.05 for the comparisons between Rotterdam and LAS cohort and are derived from the Student’s t test (continuous variables) and Pearson’s chi-square test (categorical variables).
Abbreviations: IGF-1, insulin-like growth factor 1; fg-SRL, first-generation somatostatin receptor ligand; Octreotide LAR, Octreotide long-acting release; ULN, upper limit of normal.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
